Security key
26818M108
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 69,922,072
- Total 13F value
- $929,957,219
- Share change
- +4,023,011
- Put/Call ratio
- 35%
- SEC-reported price per share
- $13.30
- Number of holders
- 123
- Value change
- +$57,596,260
- Number of buys
- 63
- Number of sells
- 54
- Shares outstanding
- 164,135,771
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2023
Institutions
123
Top holders
10
DYN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Dyne Therapeutics, Inc. SEC filings
Dyne Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 26818M108
Recent filing periods:
Ownership snapshot
Top reported holders of DYN - Dyne Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Atlas Venture Life Scienc...
Disclosed value leader
Atlas Venture Life Scienc...
Comparable rows
15/15
Latest evidence
30 Sep 2023
13F
Lead comparable stake: 6%
Showing 1-6 of 15 holder rows.
Quick read
Atlas Venture Life Science Advisors, LLC leads the comparable SEC ownership view at 6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Atlas Venture Life Science Advisors, LLC's linked filing trail.
Comparable ownership
Top 5
Atlas Venture Life Science Adviso...
6%
MPM ASSET MANAGEMENT LLC
3%
BlackRock Finance, Inc.
2%
CITADEL ADVISORS LLC
1.9%
Deep Track Capital, LP
1.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
6%
|
$88,573,623
9,885,449 shares
|
— | 30 Sep 2023 |
| MPM ASSET MANAGEMENT LLC |
13F
Company
|
3%
|
$44,363,675
4,951,303 shares
|
— | 30 Sep 2023 |
| BlackRock Finance, Inc. |
13F
Company
|
2%
|
$29,630,407
3,306,965 shares
|
— | 30 Sep 2023 |
| CITADEL ADVISORS LLC |
13F
Company
|
1.9%
|
$27,252,790
3,041,606 shares
|
— | 30 Sep 2023 |
| Deep Track Capital, LP |
13F
Company
|
1.5%
|
$21,536,901
2,403,672 shares
|
— | 30 Sep 2023 |
| VANGUARD GROUP INC |
13F
Company
|
1.4%
|
$21,184,253
2,364,314 shares
|
— | 30 Sep 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
123
Shares
69,922,072
Rows available
123
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q3 2023 Across Filers
Q3 2023 holders
114
Q4 2023 holders
123
Holder diff
9
| Investor | Q3 2023 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q3 2023 value | Q4 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend